Drug Profile
DS 8273
Alternative Names: Anti-DR5 monoclonal antibody - Daiichi Sankyo; DS-8273a; DS8273Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Developer Bristol-Myers Squibb; Daiichi Sankyo Inc; New York University School of Medicine
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Immunomodulators; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 01 Jan 2021 Phase I development in Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) is still ongoing in USA (IV) (NCT02983006)
- 01 Jan 2021 Daiichi Sankyo completes a phase I trial in Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT02983006)